Quick Answer
CNBX Pharmaceuticals Inc. reported Diluted EPS of $0.00 per share for fiscal year 2025.
CNBX Pharmaceuticals Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $0.00 | +100.0% |
| 2024 | -$0.02 | +95.2% |
| 2023 | -$0.42 | +88.3% |
| 2022 | -$3.59 | -17850.0% |
| 2021 | -$0.02 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| November 30, 2025 | $0.00 | +100.0% | — |
| May 31, 2025 | $0.00 | — | — |
| February 28, 2025 | $0.00 | +100.0% | +100.0% |
| November 30, 2024 | -$0.00 | +83.3% | — |
| May 31, 2024 | $0.00 | +100.0% | +100.0% |
| February 29, 2024 | -$0.01 | +99.2% | -66.7% |
| November 30, 2023 | -$0.01 | +98.2% | +70.0% |
| May 31, 2023 | -$0.02 | +60.0% | +98.5% |
- CNBX Pharmaceuticals Inc. showed an increase of +100.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, CNBX Pharmaceuticals Inc.’s diluted eps has grown by 100.0% (from $0.02 per share (loss) to $0.00 per share).
- The most recent figure is from CNBX Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 1, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: